112940-40-6

Basic information

• Product Name: 1-(4-aMinophenyl)-4-(pyridin-4-yl)piperazine
• Synonyms: 1-(4-aMinophenyl)-4-(pyridin-4-yl)piperazine;4-[4-(4-pyridinyl)-1-piperazinyl]Benzenamine
• CAS NO: 112940-40-6
• Molecular Weight: 254.335
• Mol File: 112940-40-6.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 1-(4-aMinophenyl)-4-(pyridin-4-yl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-aMinophenyl)-4-(pyridin-4-yl)piperazine(112940-40-6)
• EPA Substance Registry System: 1-(4-aMinophenyl)-4-(pyridin-4-yl)piperazine(112940-40-6)

Safety Data

• Hazardous Substances Data: 112940-40-6(Hazardous Substances Data)

Usage

Description

1-(4-aminophenyl)-4-(pyridin-4-yl)piperazine, also known as Ropinirole, is a medication that belongs to the class of dopamine agonists. It is characterized by its ability to stimulate dopamine receptors in the brain, which aids in regulating and improving motor function. 1-(4-aMinophenyl)-4-(pyridin-4-yl)piperazine is typically used in the treatment of neurological conditions and is available in tablet form for oral administration.

Uses

Used in Pharmaceutical Industry:
1-(4-aminophenyl)-4-(pyridin-4-yl)piperazine is used as a therapeutic agent for treating neurological conditions such as Parkinson's disease and restless leg syndrome. Its application is based on its ability to alleviate symptoms like muscle stiffness, tremors, and poor muscle control by stimulating dopamine receptors in the brain.
Used in Parkinson's Disease Treatment:
In the field of neurology, 1-(4-aminophenyl)-4-(pyridin-4-yl)piperazine is used as a dopamine agonist to manage the symptoms of Parkinson's disease. It helps improve motor function and provides relief from the challenges associated with this condition.
Used in Restless Leg Syndrome Treatment:
1-(4-aminophenyl)-4-(pyridin-4-yl)piperazine is also utilized as a treatment for restless leg syndrome, a neurological disorder characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations. Its use in this context is due to its effectiveness in targeting the dopamine receptors involved in the regulation of motor function and providing relief from the symptoms.

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 1008-91-9 4-(piperazin-1-yl)pyridine 
• 586-78-7 para-nitrophenyl bromide 
• 112940-39-3 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine 

Downstream Products

• 1007866-95-6 C₂₅H₂₇Cl₂N₅O₃S 

Relevant articles and documents

Design and synthesis of some new 1-phenyl-3/4-[4-(aryl/heteroaryl/alkyl-piperazine1-yl)-phenyl-ureas as potent anticonvulsant and antidepressant agents

A series of 1-phenyl-3/4-[4-(aryl/heteroaryl/alkyl-piperazine1-yl)-phenyl-urea derivatives (29–42) were designed, synthesized and evaluated for their anticonvulsant activity by using maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) seizure tests. The acute neurotoxicity was checked by rotarod assay. Most of the test compounds were found effective in both seizure tests. Compound 30 (1-{4-[4-(4-chloro-phenyl)-piperazin-1-yl]-phenyl}-3-phenyl-urea) exhibited marked anticonvulsant activity in MES as well as scPTZ tests. The phase II anticonvulsant quantification study of compound 30 indicates the ED50value of 28.5?mg/kg against MES induced seizures. In addition, this compound also showed considerable protection against pilocarpine induced status epilepticus in rats. Seizures induced by 3-mercaptopropionic acid model and thiosemicarbazide were significantly attenuated by compound 30, which suggested its broad spectrum of anticonvulsant activity. Interestingly, compound 30 displayed better antidepressant activity than standard drug fluoxetine. Moreover, compound 30 appeared as a non-toxic chemical entity in sub-acute toxicity studies.

NOVEL COMPOUNDS

Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain and headache diseases. The following is exemplary:

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.